- Home
- RMM vs FDMT Comparison
RMM vs FDMT Comparison
Compare RMM & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMM
- FDMT
- Stock Information
- Founded
- RMM 2019
- FDMT 2013
- Country
- RMM United States
- FDMT United States
- Employees
- RMM N/A
- FDMT N/A
- Industry
- RMM Trusts Except Educational Religious and Charitable
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- RMM Finance
- FDMT Health Care
- Exchange
- RMM Nasdaq
- FDMT Nasdaq
- Market Cap
- RMM 271.2M
- FDMT 192.2M
- IPO Year
- RMM N/A
- FDMT 2020
- Fundamental
- Price
- RMM $14.03
- FDMT $4.16
- Analyst Decision
- RMM
- FDMT Buy
- Analyst Count
- RMM 0
- FDMT 10
- Target Price
- RMM N/A
- FDMT $32.33
- AVG Volume (30 Days)
- RMM 66.5K
- FDMT 391.3K
- Earning Date
- RMM 01-01-0001
- FDMT 08-07-2025
- Dividend Yield
- RMM 7.33%
- FDMT N/A
- EPS Growth
- RMM N/A
- FDMT N/A
- EPS
- RMM 0.96
- FDMT N/A
- Revenue
- RMM N/A
- FDMT $23,000.00
- Revenue This Year
- RMM N/A
- FDMT $13,048.65
- Revenue Next Year
- RMM N/A
- FDMT N/A
- P/E Ratio
- RMM $15.55
- FDMT N/A
- Revenue Growth
- RMM N/A
- FDMT N/A
- 52 Week Low
- RMM $12.32
- FDMT $2.24
- 52 Week High
- RMM $16.10
- FDMT $28.93
- Technical
- Relative Strength Index (RSI)
- RMM 73.02
- FDMT 51.31
- Support Level
- RMM $13.51
- FDMT $4.23
- Resistance Level
- RMM $14.07
- FDMT $4.42
- Average True Range (ATR)
- RMM 0.10
- FDMT 0.26
- MACD
- RMM 0.08
- FDMT -0.00
- Stochastic Oscillator
- RMM 95.36
- FDMT 58.54
About RMM RiverNorth Managed Duration Municipal Income Fund Inc.
RiverNorth Managed Duration Muni Inc Fd is a United States based diversified, closed-end management investment company. Its primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.